Gene therapies can induce the expression of anti-VEGF molecules in native ocular cells, such as the retinal pigment epithelium to offer more durable VEGF inhibition as compared with current molecules delivered by intravitreal injection. The majority of these therapeutics utilize adeno-associated viral vectors to deliver gene therapies, but lentiviral and CRISPR/Cas methodologies can also be employed. Some gene therapeutics that are under current clinical testing are: LX102 in phase I and phase II testing (NCT06198413, NCT05831007, and VENUS/NCT06196840), ADVM-022 in phase II testing (LUNA/NCT05536973, INFINITY/NCT04418427, OPTIC-EXT/NCT04645212, and INFINITY-EXT/NCT05607810), SKG0106 in phase I and phase II testing (NCT06213038, NCT05986864, NCT06237777, and NCT06346600), RRG001 in phase I and phase II testing (NCT06141460 and NCT06412224), EXG102-031 in phase I and phase II testing (NCT06183814 and Everest/NCT05903794), FT-003 in phase I and phase II testing (NCT06492876 and NCT06492863), KH658 in phase I and phase II testing (NCT06458595), KH631 in phase I and phase II testing (NCT05657301 and NCT05672121), RGX-314 in phase II and phase III testing (AAVIATE/NCT04514653, ASCENT/NCT05407636, ATMOSPHERE/NCT04704921, ALTITUDE/NCT04567550, and SRLTFU/NCT03999801), 4D-150 in phase I and phase II testing (NCT05197270 and NCT05930561), HG202 in early phase I testing (SIGHT-I/NCT06031727), ABI-110 in phase I and phase II testing (NCT06550011), BD311 in early phase I testing (NCT05099094), and LX109 (NCT06022744).